Ongoing important trials
FOXHIPECT4 — neoadjuvant FOLFOX ± HIPEC in locally advanced colon cancer
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT06783491
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A study is testing whether heated abdominal mitomycin added around neoadjuvant treatment helps in locally advanced colon cancer.
Why promising? Randomizes a proactive neoadjuvant ± HIPEC strategy in high-risk locally advanced colon cancer.
What is not proven? Benefit not shown. This protocol uses mitomycin HIPEC; it is not the same question as oxaliplatin HIPEC in PRODIGE 7.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting (n≈1083). Neoadjuvant FOLFOX ± mitomycin HIPEC. No results yet; distinct from PRODIGE 7 oxaliplatin HIPEC context.
Cancer / population: Colon, Peritoneal metastasis — Lokal ileri kolon (cT4 / cT3 >5 mm), M0
Intervention: Neoadjuvan FOLFOX ± mitomycin HIPEC + adjuvan FOLFOX
Primary endpoint: 36 ay DFS
Limitations: Sonuç yok; HIPEC endikasyonunu genelleme; ilaç (mitomisin) tutarlı okunmalı.